Breaking News, Promotions & Moves

New Amsterdam Sciences Appoints Executive Vice President

Dr. Christopher van de Wetering brings decades of governmental experience.

Author Image

By: Charlie Sternberg

Associate Editor

New Amsterdam Sciences, a privately held bio- science company, has appointed Christopher van de Wetering, Ph.D. as executive vice president.    Dr. van de Wetering is charged with general operations management, preclinical and clinical drug development including manufacturing and formulation as well as bringing the company’s anti-inflammatory therapeutic for treatment of COVID-19, NAS150, to market. Van de Wetering is also the company’s lead on the countermeasure development pipeline.   “Hav...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters